Cel-Sci Corp. (CVM)

May 30, 2025

CVM stock touches 52-week low at $2.32 amid sharp annual decline By Investing.com - Investing.com South Africa

May 30, 2025

May 29, 2025

CVM stock touches 52-week low at $2.32 amid sharp annual decline - Investing.com Australia

May 29, 2025

May 23, 2025

CEL-SCI Closes $5 Million Public Offering - marketscreener.com

May 23, 2025

May 23, 2025

Cancer Immunotherapy Firm CEL-SCI Secures $5M Funding to Advance Multikine Treatment - Stock Titan

May 23, 2025

May 23, 2025

CVM Stock Offering Priced Below Previous Closing Value | CVM Stock News - GuruFocus

May 23, 2025

May 22, 2025

Dow Moves Higher; US Initial Jobless Claims Fall - Benzinga

May 22, 2025

May 22, 2025

CEL-SCI (CVM) Prices Public Offering Amid Stock Slump - GuruFocus

May 22, 2025

May 22, 2025

CEL-SCI Prices Offering of 2 Million Shares - marketscreener.com

May 22, 2025

May 22, 2025

CEL-SCI (CVM) Prepares to Submit Breakthrough Medicine Applicati - GuruFocus

May 22, 2025

May 22, 2025

Pre-market Movers: VIGL, CVM, KDLY, VTAK... - RTTNews

May 22, 2025

May 21, 2025

CVM Stock Offering Priced Below Previous Closing Value | CVM Sto - GuruFocus

May 21, 2025

May 21, 2025

Cel-Sci Says Prices Public Offering Of 2 Million Shares At $2.50 Per Share - marketscreener.com

May 21, 2025

May 21, 2025

CEL-SCI Raises $5M in New Stock Offering: Cancer Immunotherapy Program Multikine Gets Fresh Funding - Stock Titan

May 21, 2025

May 21, 2025

CVM stock touches 52-week low at $4.67 amid sharp annual decline By Investing.com - Investing.com South Africa

May 21, 2025

May 21, 2025

CEL-SCI Announces Planned Public Offering; Shares Fall After Hours - marketscreener.com

May 21, 2025

May 21, 2025

CEL-SCI announces public stock offering to fund cancer therapy By Investing.com - Investing.com Canada

May 21, 2025

May 21, 2025

CEL-SCI Corporation (CVM) Plans Public Offering for R&D and Corporate Needs | CVM Stock News - GuruFocus

May 21, 2025

May 21, 2025

CEL-SCI announces public stock offering to fund cancer therapy - Investing.com

May 21, 2025

May 21, 2025

CEL-SCI Announces Strategic Public Offering: Cancer Immunotherapy Development Gets Major Funding Push - Stock Titan

May 21, 2025

May 21, 2025

CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia - BioSpace

May 21, 2025

May 21, 2025

CVM stock touches 52-week low at $4.67 amid sharp annual decline - Investing.com Canada

May 21, 2025

May 21, 2025

CEL-SCI Completes Saudi Breakthrough Medicine Designation Application for Multikine Cancer Drug - marketscreener.com

May 21, 2025

May 21, 2025

CEL-SCI seeks SFDA nod for cancer drug Multikine By Investing.com - Investing.com Canada

May 21, 2025

May 21, 2025

CEL-SCI seeks SFDA nod for cancer drug Multikine - Investing.com

May 21, 2025

May 21, 2025

CEL-SCI (CVM) Prepares to Submit Breakthrough Medicine Application in Saudi Arabia | CVM Stock News - GuruFocus

May 21, 2025

May 21, 2025

Revolutionary Cancer Drug Shows 73% Survival Rate, Nears Fast-Track Approval in Saudi Arabia - Stock Titan

May 21, 2025

May 20, 2025

CEL-SCI Implements 1-for-30 Stock Split To Support Share Price - Nasdaq

May 20, 2025

May 19, 2025

CEL-SCI approves 1-for-30 stock combination By Investing.com - Investing.com South Africa

May 19, 2025

May 19, 2025

CEL-SCI (CVM) Approves 1-for-30 Stock Consolidation | CVM Stock News - GuruFocus

May 19, 2025

May 19, 2025

CEL-SCI approves 1-for-30 stock combination - Investing.com Australia

May 19, 2025

May 19, 2025

CEL-SCI's Board Approves 1-for-30 Share Combination - marketscreener.com

May 19, 2025

May 19, 2025

CEL-SCI Announces Combination of Common Stock | CVM Stock News - GuruFocus

May 19, 2025

May 19, 2025

CEL-SCI expects 1 for 30 combination of common stock to be implemented on May 20 - TipRanks

May 19, 2025

May 19, 2025

CEL-SCI Plans Major 1:30 Reverse Split as CEO Hints at Upcoming Catalysts - Stock Titan

May 19, 2025

May 16, 2025

StockNews.com Begins Coverage on CEL-SCI (NYSE:CVM) - Defense World

May 16, 2025

May 15, 2025

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results | C - GuruFocus

May 15, 2025

May 15, 2025

CEL-SCI Cancer Drug Shows 95% Quality of Life Success in Phase 3 Trial | CVM Stock News - Stock Titan

May 15, 2025

May 15, 2025

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results - Business Wire

May 15, 2025

May 15, 2025

Cel-Sci: Fiscal Q2 Earnings Snapshot - New Haven Register

May 15, 2025

May 08, 2025

CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com - Defense World

May 08, 2025

May 04, 2025

CEL-SCI Co. (NYSE:CVM) Shares Sold by Geode Capital Management LLC - Defense World

May 04, 2025

May 02, 2025

LD Micro 360 Companies --Set to Present this Week. - ACCESS Newswire

May 02, 2025

May 02, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 02, 2025

May 02, 2025

Take off with Cel-Sci Corp (CVM): Get ready for trading - Sete News

May 02, 2025

May 02, 2025

Top investors say Ares Management Corp (ARES) ticks everything they need - Sete News

May 02, 2025

May 01, 2025

A stock that deserves closer examination: Cel-Sci Corp (CVM) - uspostnews.com

May 01, 2025

Apr 30, 2025

Investing in Cel-Sci Corp (CVM) Is Getting More Attractive - knoxdaily.com

Apr 30, 2025

Apr 30, 2025

CVM’s Stock Journey: What Investors Need to Know About Cel-Sci Corp’s Performance - investchronicle.com

Apr 30, 2025

Apr 30, 2025

Curbline Properties Corp (CURB) Becoming More Attractive for Investors - knoxdaily.com

Apr 30, 2025

Apr 30, 2025

Metric Analysis: Coca-Cola Femsa S.A.B. DE C.V. ADR (KOF)’s Key Ratios in the Limelight - DWinneX

Apr 30, 2025

Apr 30, 2025

Analyzing Ratios: Cel-Sci Corp (CVM)’s Financial Story Unveiled - DWinneX

Apr 30, 2025